Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug

 
• By Jessica Merrill

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

Heart health care medical cardiovascular disease concept and organ donor donation for life giving charity campaign with healthy red love heart on aging woman's hand support - Image
Pfizer is going big and broad in cardiovascular disease • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas